This week’s Q2 update and conference call by Prometic highlighted just how important a part one of the Company’s smallest investigational indications (Alström Syndrome) is playing in driving its partnering and clinical strategy. Why is this?

17 Aug 2018
Q2 highlights: strong Alström data opening up multiple options. Partnering and investor interest growing

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 highlights: strong Alström data opening up multiple options. Partnering and investor interest growing
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
17 Aug 2018 -
Author:
Derren Nathan -
Pages:
7 -
This week’s Q2 update and conference call by Prometic highlighted just how important a part one of the Company’s smallest investigational indications (Alström Syndrome) is playing in driving its partnering and clinical strategy. Why is this?